Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, and its news flow reflects both internal pipeline progress and partner-driven milestones. The company regularly issues updates on its XmAb® drug candidates, including T-cell engaging bispecific antibodies and Fc-engineered antibodies that use its XmAb and Xtend™ technologies.
Investors following XNCR news can expect detailed announcements on clinical trial progress across oncology and autoimmune indications. Recent releases have covered Phase 1 and Phase 2 studies of programs such as XmAb819 for advanced clear cell renal cell carcinoma, XmAb541 for gynecologic and germ cell tumors, plamotamab for rheumatoid arthritis, XmAb657 for idiopathic inflammatory myopathies, and XmAb942 and XmAb412 for inflammatory bowel and other autoimmune diseases. These updates often include safety and efficacy summaries, dose-escalation status, and plans for pivotal or proof-of-concept studies.
Xencor’s news stream also features financial results and guidance, including quarterly earnings, cash and marketable securities levels, and commentary on how its balance sheet supports research and development plans. In addition, the company reports on intellectual property developments, such as U.S. patent issuances that extend royalty terms on Xtend-based antibodies like Ultomiris, and on collaboration milestones with partners including Amgen, Astellas, Incyte and Zenas Biopharma.
Corporate governance and strategic updates, such as board appointments and participation in investor conferences, are also common topics. For investors and analysts, the XNCR news page provides a centralized view of how Xencor’s XmAb technology platform is progressing in the clinic, how partnered programs are advancing, and how these activities translate into milestones, royalties and long-term development plans.
Xencor, a clinical-stage biopharmaceutical company focusing on engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, announced that its CEO, Bassil Dahiyat, will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Virtual Conference. The event is set for May 19, 2021, at 1:20 p.m. ET. Investors can access a live webcast on the company's website, with a replay available for 30 days afterward. Xencor has 21 clinical candidates utilizing its XmAb technology.
Xencor, a clinical-stage biopharmaceutical company, reported Q1 2021 financial results, achieving a total revenue of $34 million, an increase from $32.4 million in Q1 2020. The net loss narrowed to $2.5 million or $(0.04) per share, compared to a loss of $8.1 million the previous year. Cash and equivalents amounted to $577.1 million. Recently, Xencor initiated a Phase 1 study for XmAb564 and presented preclinical data at the AACR meeting. Future clinical studies are planned for XmAb717 and Tidutamab.
Xencor, Inc. (NASDAQ: XNCR) has initiated a Phase 1 clinical study for XmAb564, targeting autoimmune diseases. The first subject has been dosed in this randomized, double-blind, placebo-controlled trial, which evaluates the safety and tolerability of XmAb564 in healthy volunteers. XmAb564 is designed to selectively activate regulatory T cells while minimizing activation of other immune cells, aimed at improving therapeutic outcomes. Preliminary studies indicate it has favorable pharmacologic properties and promotes sustained Treg proliferation.
Xencor, Inc. (NASDAQ: XNCR) announced its plans to release first quarter 2021 financial results after market close on May 5, 2021. A conference call will be held the same day at 4:30 p.m. ET to discuss the results and provide a corporate update. Interested parties can access the call by dialing (877) 359-9508 or through an online webcast available on Xencor's website. The company is focused on developing engineered monoclonal antibodies and cytokines for cancer and autoimmune disease treatments, with 21 candidates in clinical development.
Xencor, Inc. (NASDAQ:XNCR) announced new data presentation from its preclinical bispecific antibody and IL-12-Fc cytokine programs at the AACR Annual Meeting. The data showcases the potential of CD28 and XmAb 2+1 platforms, emphasizing their engineered cytokines' enhanced therapeutic indices. Notably, Xencor plans to submit an IND for their XmAb819 bispecific antibody in 2021 and start a Phase 1 study in early 2022. The IL-12-Fc fusions showed significant anti-tumor activity in preclinical models, indicating a promising future for Xencor's innovations in cancer therapies.
Xencor, Inc. (NASDAQ: XNCR) announced it will present preclinical data on three XmAb® bispecific antibody programs and the IL-12-Fc cytokine program at the AACR Annual Meeting virtually from April 10-15, 2021. Key abstracts include:
- IL12 Fc-fusions with strong anti-tumor activity.
- PDL1-targeted bispecific antibodies enhancing T cell activation.
- Bispecific claudin-6 x CD3 antibodies targeting ovarian cancer.
- Affinity tuned XmAb® antibodies showing activity in liver cancer models.
Posters will be available for registrants starting April 10.
Xencor, Inc. (NASDAQ:XNCR) announced that its CEO, Bassil Dahiyat, Ph.D., will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on March 10, 2021, at 2:25 p.m. ET. A live webcast will be available on the company's website, with a replay accessible for 30 days afterward. Xencor focuses on developing engineered monoclonal antibodies and cytokines for treating cancer and autoimmune diseases, with 20 candidates currently in clinical development utilizing its XmAb® antibody engineering technology.
Xencor, Inc. (NASDAQ:XNCR) and UCLA Technology Development Group have partnered to develop new therapeutic antibodies using Xencor's XmAb® technology. This collaboration aims to expedite the creation of innovative biologics, addressing previously challenging biological targets. Xencor's platforms allow for the production of bispecific antibodies and engineered cytokines, with 20 clinical-stage candidates currently advancing. Notably, two Xencor-engineered antibodies have already received FDA approval for treating severe blood disorders and non-Hodgkin lymphoma.
Xencor, Inc. (NASDAQ:XNCR) reported its financial results for Q4 and full year 2020, showing revenues of $41.9 million for Q4 and $122.7 million for the year, down from $3.5 million and $156.7 million in 2019, respectively. The company reported a net loss of $13.7 million for Q4, significantly improved from a $26.9 million loss in 2019, but a full-year net loss of $69.3 million compared to a profit of $26.9 million in 2019. Xencor plans to end 2021 with $425-$475 million in cash, supporting ongoing R&D initiatives, including studies of its bispecific antibodies.
Xencor, Inc. (NASDAQ:XNCR) will release its fourth quarter and full year 2020 financial results on February 23, 2021, after market closure. A conference call and webcast for discussion of the results and corporate updates will follow at 4:30 p.m. ET. Interested parties can access the call via phone or through the company's website. Xencor is engaged in developing engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, with 20 candidates in clinical development utilizing its XmAb technology.